|
Recent RNAi-Related Deals of Note
|
||
| Companies |
Deal
|
Date Announced
|
| Benitec and Artemis | Benitec granted a non-exclusive license to its expressed RNAi technology to Artemis for use in developing transgenic rat and mouse models. | Aug. 25, 2004 |
| Nucleonics and Apath | Nucleonics non-exclusively licensed from Apath a patent covering the use of the 3' non-translated region of the hepatitis C viral genome. | Nov. 17, 2004 |
| Galadeno and Celgene | Galadeno agreed to provide its adenoviral siRNA and cDNA libraries, as well as its SilenceSelect and FlexSelect technologies, to Celgene for target discovery. | Nov. 18, 2004 |
| GE Healthcare and Dharmacon | GE Healthcare became the exclusive distribution agent for Dharmacon's RNAi products in Japan. | Nov. 22, 2004 |
| Sirna Therapeutics and Skinetics | Sirna acquired privately held dermatology firm Skinetics, picking up its technology related to the use of siRNAs to knock down a gene associated with hair growth. | Dec. 8, 2004 |
| Alnylam Pharmaceuticals and GeneCare |
Alnylam licensed to Japanese drug developer GeneCare RNAi intellectual property for use in discovering, developing, and marketing RNAi therapies against two genes associated with cancer. Alnylam acquired the right to negotiate US co-development and co-marketing rights for the drugs as part of the deal. | Jan. 6, 2005 |
| Sirna Therapeutics and Targeted Genetics | The companies agreed to collaborate on the development of an RNAi-based treatment for Huntington's disease. They will share costs, revenues, and promotion rights. | Jan. 11, 2005 |
| B-Bridge and RZPD | B-Bridge signed on to distribute for the German Resource Center for Genome Research (RZPD) products and services, including esiRNA-related products, in North America and Japan. | Jan. 20, 2005 |
| Dharmacon and Genentech | Dharmacon agreed to provide Genentech with a range of siRNA reagents including its Human Druggable Genome library. | Jan. 21, 2005 |
| Benitec and Garvan Institute of Medical Research | Benitec licensed from Garvan intellectual property related to the c-Cbl gene, which is believed to play a role in obesity and diabetes. Benitec also entered talks to form a research collaboration with Garvan. | Feb. 3, 2005 |
| Alnylam Pharmaceuticals and Medtronic |
The companies partnered on the development of therapies for neurodegenerative disorders. Alnylam is responsible for early stage development of potential drugs, with Medtronic handling late-stage development and commercialization efforts of a drug/device product. | Feb. 9, 2005 |
| Sigma-Aldrich and Proligo |
Sigma acquired Proligo from Degussa in a bid to extend its gene-silencing capabilities into the RNAi field. | Feb. 16, 2005 (Deal consummated April 1.) |
| Benitec and CombiMatrix | The companies inked an intellectual property cross-licensing deal allowing each to use the other's technology to pursue the development of RNAi-based therapeutics in their respective areas of interest. As part of the deal, Benitec received from CombiMatrix IP related to the use of siRNA cocktails. | Feb. 23, 2005 |
| Alnylam Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics |
Alnylam formed a collaboration with CFFT to discover siRNAs that restore the proper function to the cystic fibrosis transmembrane conductance regulator, a protein linked to cystic fibrosis. | March 16, 2005 |
| Quark Biotech and Atugen |
The companies signed a deal to work together on siRNAs targeting the gene RTP801, which is associated with neovascularization, permeability of vasculature, and apoptosis. | Unannounced. First reported in RNAi News on March 18, 2005. |
| Benitec and Genoway | Benitec provided Genoway with a non-exclusive license to its expressed RNAi technology for use in developing transgenic animals. | March 22, 2005 |
| Alnylam Pharmaceuticals and Dowpharma |
Dowpharma signed on to manufacture and supply RNAi drug candidates for use by Alnylam in its drug development programs. | March 29, 2005 |
| Benitec and Alnylam Pharmaceuticals | The companies granted each other the option to non-exclusively license the other's RNAi-related intellectual property for drug development. | April 12, 2005 |
| Galadeno and Cystic Fibrosis Foundation | Galadeno agreed to use its adenoviral siRNA SilenceSelect and cDNA FlexSelect collections and know-how in assay design to discover and validate novel drug targets for the development of new cystic fibrosis therapies for CFF. | April 14, 2005 |
| Dharmacon and Millennium Pharmaceuticals | Dharmacon signed a deal to provide Millennium with a genome-wide siRNA library covering about 22,000 human genes. | May 5, 2005 |
| Cenix BioScience and Definiens | The companies signed a licensing and co-marketing deal in the area of high-content screening. The arrangement calls for Cenix's integration of Definiens' Cellenger image analysis software system into its high-content RNAi-based screening infrastructure. | May 9, 2005 |
| Open Biosystems and the RNAi Consortium | Open Biosystems signed on to become the distributor of the Broad Institute's RNAi Consortium's short hairpin RNA library for the entire human genome. | Unannounced. First reported in RNAi News on May 13, 2005.) |
| Alnylam Pharmaceuticals and Ambion |
Alnylam non-exclusively licensed to Ambion the right to provide RNAi-based research products and services under the Kreutzer-Limmer patent estate. | June 8, 2005 |
| Intradigm and Acuity Pharmaceuticals | Intradigm exclusively licensed its ophthalmic drug discovery and delivery platforms to Acuity Pharmaceuticals. The companies also agreed to collaborate on the development of topical and other formulations of Acuity's RNAi-based age-related macular degeneration therapy, Cand5. | June 9, 2005 |
Recent RNAi-related Deals of Note, June 2005
Premium